Vascular remodeling-associated hypertension leads to left ventricular hypertrophy and contractile dysfunction in profilin-1 transgenic mice

Journal of Cardiovascular Pharmacology

Volumn 60, Issue 6, 2012, Pages 544-552

  Elnakish, Mohammad T ^a,b   Hassanain, Hamdy H ^a,b   Janssen, Paul M L ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

calcium; contraction; isoproterenol; left ventricular hypertrophy; papillary muscles; profilin 1

Indexed keywords

ACTIN RELATED PROTEIN; CALCIUM ION; PROFILIN I; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BETA ADRENERGIC STIMULATION; BODY WEIGHT; CONTROLLED STUDY; ECHOCARDIOGRAPHY; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CONTRACTILITY; HEART PAPILLARY MUSCLE; HEART RATE; HEART WEIGHT; HYPERTENSION; IN VIVO STUDY; ISOMETRIC EXERCISE; MOUSE; MUSCLE STRENGTH; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QRS COMPLEX; QT INTERVAL; SYSTOLIC DYSFUNCTION; VASCULAR REMODELING ASSOCIATED HYPERTENSION;

ADRENERGIC BETA-AGONISTS; ANIMALS; CALCIUM; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MICE; MICE, TRANSGENIC; MYOCARDIAL CONTRACTION; PAPILLARY MUSCLES; PROFILINS; SYSTOLE; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, RIGHT;

EID: 84871608364     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e318271225d     Document Type: Article

References (54)

1. Mulvany MJ. Small artery remodeling in hypertension. Curr Hypertens Rep. 2002;4:49-55.
2. Park JB, Schiffrin EL. Small artery remodeling is the most prevalent (earliest?) form of target organ damage in mild essential hypertension. J Hypertens. 2001;19:921-930.
3. Kenchaiah S, Pfeffer MA. Cardiac remodeling in systemic hypertension. Med Clin North Am. 2004;88:115-130.
4. Berenji K, Drazner MH, Rothermel BA, et al. Does load-induced ventricular hypertrophy progress to systolic heart failure? Am J Physiol Heart Circ Physiol. 2005;289:H8-H16.
5. Diwan A, Dorn GW II. Decompensation of cardiac hypertrophy: cellular mechanisms and novel therapeutic targets. Physiology. 2007;22:56-64.
6. McKinsey TA, Kass DA. Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface. Nat Rev Drug Discov. 2007;6: 617-635.
7. Elnakish MT, Hassanain HH. Profilin, and vascular diseases. In: Ekinci D, ed. Biochemistry. Rijeka, Croatia: InTech, 2012:65-106. Available at: http://www.intechopen.com/books/biochemistry/profilinand-vascular-diseases. Accessed August 20, 2012.
8. Moustafa-Bayoumi M, Alhaj MA, El-Sayed O, et al. Vascular hypertrophy and hypertension caused by transgenic overexpression of profilin 1. J Biol Chem. 2007;282:37632-37639.
9. Hassona MD, Abouelnaga ZA, Elnakish MT, et al. Vascular hypertrophy-associated hypertension of profilin 1 transgenic mouse model leads to functional remodeling of peripheral arteries. Am J Physiol Heart Circ Physiol. 2010;298:H2112-H2120.
10. Hassona MD, Elnakish MT, Abouelnaga ZA, et al. The effect of selective antihypertensive drugs on the vascular remodeling-associated hypertension: insights from a profilin 1 transgenic mouse model. J Cardiovasc Pharmacol. 2011;57:550-558.
11. Elnakish MT, Awad MM, Hassona MD, et al. Cardiac remodeling caused by transgenic over-expression of a corn Rac gene. Am J Physiol Heart Circ Physiol. 2011;301:H868-H880.
12. Janssen PML, Hunter WC. Force, not sarcomere length, correlates with prolongation of isosarcometric contraction. Am J Physiol Heart Circ Physiol. 1995;269(2 pt 2):H676-H685.
13. Janssen PM, Hiranandani N, Mays TA, et al. Utrophin deficiency worsens cardiac contractile dysfunction present in dystrophin-deficient mdx mice. Am J Physiol Heart Circ Physiol. 2005;289:H2373-H2378.
14. Rodriguez EK, Hunter WC, Royce MJ, et al. A method to reconstruct myocardial sarcomere lengths and orientations at transmural sites in beating canine hearts. Am J Physiol Heart Circ Physiol. 1992;263(1 pt 2): H293-H306.
15. Shorofsky SR, Aggarwal R, Corretti M, et al. Cellular mechanisms of altered contractility in the hypertrophied heart. Big heart, big sparks. Circ Res. 1999;84:424-434.
16. Frank O. Zur dynamik des Herzmuskels. Z Biol. 1895;32:370-447.
17. Starling EH. The Lineacre Lecture on the Law of the Heart. London, United Kingdom: Longman Greens; 1918.
18. Bowditch HP. Ueber die eigenthuemlichkeiten der reizbarkeit, welche die muskelfasern des herzens zeigen. Ber Sachs Ges (Akad) Wiss. 1871;23:652-689.
19. Hallbäck-Nordlander M, Noresson E, Thorén P. Hemodynamic consequences of left ventricular hypertrophy in spontaneously hypertensive rats. Am J Cardiol. 1979;44:986-993.
20. Pfeffer MA, Pfeffer JM, Frohlich ED. Pumping ability of the hypertrophying left ventricle of the spontaneously hypertensive rat. Circ Res. 1976;38:423-429.
21. Spech MM, Ferrario CM, Tarazi RC. Cardiac pumping ability following reversal of hypertrophy and hypertension in spontaneously hypertensive rats. Hypertension. 1980;2:75-82.
22. Averill DB, Ferrario CM, Tarazi RC, et al. Cardiac performance in rats with renal hypertension. Circ Res. 1976;38:280-288.
23. Strauer BE. Ventricular function and coronary hemodynamics in hypertensive heart disease. Am J Cardiol. 1979;44:999-1006.
24. Newman WH, Webb JG. Adaptation of left ventricle to chronic pressure overload: response to inotropic drugs. Am J Physiol. 1980;238:H134-H143.
25. Cooper G 4th, Satava RM Jr, Harrison CE, et al. Mechanisms for the abnormal energetics of pressure-induced hypertrophy of cat myocardium. Circ Res. 1973;33:213-223.
26. Spann JF Jr, Buccino RA, Sonnenblick EH, et al. Contractile state of cardiac muscle obtained from cats with experimentally produced ventricular hypertrophy and heart failure. Circ Res. 1967;21:341-354.
27. Gunning JF, Coleman HN 3rd. Myocardial oxygen consumption during experimental hypertrophy and congestive heart failure. J Mol Cell Cardiol. 1973;5:25-38.
28. Carey RA, Bove AA, Coulson RL, et al. Recovery of myosin ATPase after relief of pressure-overload hypertrophy and failure. Am J Physiol. 1978;234(6):H711-H717.
29. Coulson RL, Yazdanfar S, Rubio E, et al. Recuperative potential of cardiac muscle following relief of pressure overload hypertrophy and right ventricular failure in the cat. Circ Res. 1977;40:41-49.
30. Bing OH, Matsushita S, Fanburg BL, et al. Mechanical properties of rat cardiac muscle during experimental hypertrophy. Circ Res. 1971;28:234-245.
31. Satoh S, Ueda Y, Koyanagi M, et al. Chronic inhibition of Rho kinase blunts the process of left ventricular hypertrophy leading to cardiac contractile dysfunction in hypertension-induced heart failure. J Mol Cell Cardiol. 2003;35:59-70.
32. Novaes MA, Stefanon I, Mill JG, et al. Contractility changes of the right and ventricular muscle after chronic myocardial infarction. Braz J Med Biol Res. 1996;29:1683-1690.
33. Janssen PM, Stull LB, Leppo MK, et al. Selective contractile dysfunction of left, not right, ventricular myocardium in the SHHF rat. Am J Physiol Heart Circ Physiol. 2003;284:H772-H778.
34. Zobel C, Brixius K, Pietsch M, et al. Unchanged sarcoplasmic reticulum Ca2+-ATPase activity, reduced Ca2+ sensitivity, and negative force-frequency relationship in transgenic rats overexpressing the mouse renin gene. J Mol Med (Berl). 1998;76:533-544.
35. Buckley NM, Penefsky ZJ, Litwak RS.Comparative force-frequency relationships in human and other mammalian ventricular myocardium. Pflugers Arch. 1972;332(4):259-270.
36. Georgakopoulos D, Kass D. Minimal force-frequency modulation of inotropy and relaxation of in situ murine heart. J Physiol. 2001;534(Pt. 2):535-545.
37. Janssen PM, Periasamy M. Determinants of frequency-dependent contraction and relaxation of mammalian myocardium. J Mol Cell Cardiol. 2007;43:523-531.
38. Rice JJ, Jafri MS, Winslow RL. Modeling short-term interval-force relations in cardiac muscle. Am J Physiol Heart Circ Physiol. 2000;278: H913-H931.
39. Redel A, Baumgartner W, Golenhofen K, et al. Mechanical activity and force-frequency relationship of isolated mouse papillary muscle: effects of extracellular calcium concentration, temperature and contraction type. Pflugers Arch. 2002;445(2):297-304.
40. Gao WD, Perez NG, Marban E. Calcium cycling and contractile activation in intact mouse cardiac muscle. J Physiol (Lond). 1998;507(pt 1): 175-184.
41. Stull LB, Leppo M, Marban E, et al. Physiological determinants of contractile force generation and calcium handling in mouse myocardium. J Mol Cell Cardiol. 2002;34:1367-1376.
42. Brooks WW, Apstein CS. Effect of treppe on isovolumic function in the isolated blood-perfused mouse heart. J Mol Cell Cardiol. 1996;28: 1817-1822.
43. Bluhm WF, Kranias EG, Dillmann WH, et al. Phospholamban: a major determinant of the cardiac force-frequency relationship. Am J Physiol. 2000;278(1):H245-H255.
44. Meyer M, Bluhm WF, He H, et al. Phospholamban-to-SERCA2 ratio controls the force-frequency relationship. Am J Physiol. 1999;276(3 pt 2):H779-H785.
45. Wolska BM, Solaro RJ. Method for isolation of adult mouse cardiac myocytes for studies of contraction and microfluorimetry. Am J Physiol. 1996;271(3 pt 2):H1250-H1255.
46. Raman S, Kelley MA, Janssen PM. Effect of muscle dimensions on trabecular contractile performance under physiological conditions. Pflugers Arch. 2006;451(5):625-630.
47. Gende OA, Mattiazzi A, Camilion MC, et al. Renal hypertension impairs inotropic isoproterenol effect without beta-receptor changes. Am J Physiol. 1985;249(4 pt 2):H814-H819.
48. Saragoca MA, Tarazi RC. Impaired cardiac contractile response to isoproterenol in the spontaneously hypertensive rat. Hypertension. 1981;3:380-385.
49. Kumano K, Upsher ME, Khairallah PA. Beta adrenergic receptor response coupling in hypertrophied hearts. Hypertension. 1983;5(2 pt 2): 175-183.
50. Limas C, Limas CJ. Reduced number of b-adrenergic receptors in the myocardium of spontaneously rats. Biochem Biophys Res Commun. 1987;83:710-716.
51. Brooks WW, Bing OH, Boluyt MO, et al. Altered inotropic responsiveness and gene expression of hypertrophied myocardium with captopril. Hypertension. 2000;35:1203-1209.
52. Cheng JF, Ni GH, Chen MF, et al. Involvement of profilin-1 in angiotensin II-induced vascular smooth muscle cell proliferation. Vascul Pharmacol. 2011;55:34-41.
53. Zhong JC, Ye JY, Jin HY, et al. Telmisartan attenuates aortic hypertrophy in hypertensive rats by the modulation of ACE2 and profilin-1 expression. Regul Pept. 2011;166:90-97.
54. Caglayan E, Romeo GR, Kappert K, et al. Profilin-1 is expressed in human atherosclerotic plaques and induces atherogenic effects on vascular smooth muscle cells. PLoS One. 2010;5(10):e13608.